Your browser doesn't support javascript.
Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.
Pharmacogenomics ; 19(4): 361-373, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29469670
Childhood acute lymphoblastic leukemia survival rates have increased remarkably during last decades due, in part, to intensive treatment protocols. However, therapy resistance and toxicity are still two important barriers to survival. In this context, pharmacoepigenetics arises as a tool to identify new predictive markers, required to guide clinicians on risk stratification and dose individualization. The present study reviews current evidence about miRNA implication on childhood acute lymphoblastic leukemia therapy resistance and toxicity. A total of 12 studies analyzing differential miRNA expression in relation to drug resistance and six studies exploring the association between miRNAs-related SNPs and drug-induced toxicities were identified. We pointed out to miR-125b together with miR-99a and/or miR-100 overexpression as markers of vincristine resistance and rs2114358 in mir-1206 as mucositis marker as the most promising results.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: MicroRNAs / Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Aspecto clínico: Etiologia / Predição / Prognóstico / Terapia Limite: Animais / Humanos Idioma: Inglês Revista: Pharmacogenomics Assunto da revista: Farmacologia / Genética Médica Ano de publicação: 2018 Tipo de documento: Artigo País de afiliação: Espanha